These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23741352)
1. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. Kijima T; Koga F; Fujii Y; Yoshida S; Tatokoro M; Kihara K PLoS One; 2013; 8(5):e64615. PubMed ID: 23741352 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Zhu H; Wang Z; Xu Q; Zhang Y; Zhai Y; Bai J; Liu M; Hui Z; Xu N Cancer Biol Ther; 2012 Apr; 13(6):401-7. PubMed ID: 22262126 [TBL] [Abstract][Full Text] [Related]
3. Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Hui Z; Tretiakova M; Zhang Z; Li Y; Wang X; Zhu JX; Gao Y; Mai W; Furge K; Qian CN; Amato R; Butler EB; Teh BT; Teh BS Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):288-95. PubMed ID: 19100922 [TBL] [Abstract][Full Text] [Related]
4. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells. Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451 [TBL] [Abstract][Full Text] [Related]
5. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Dovhey SE; Ghosh NS; Wright KL Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775 [TBL] [Abstract][Full Text] [Related]
6. CCN1, a candidate target for zoledronic acid treatment in breast cancer. Espinoza I; Liu H; Busby R; Lupu R Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426 [TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells. Valenti MT; Giannini S; Donatelli L; Realdi G; Lo Cascio V; Dalle Carbonare L J Endocrinol Invest; 2010 Apr; 33(4):244-9. PubMed ID: 19915386 [TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe. Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237 [TBL] [Abstract][Full Text] [Related]
9. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Souchek JJ; Baine MJ; Lin C; Rachagani S; Gupta S; Kaur S; Lester K; Zheng D; Chen S; Smith L; Lazenby A; Johansson SL; Jain M; Batra SK Br J Cancer; 2014 Sep; 111(6):1139-49. PubMed ID: 25025965 [TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473 [TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320 [TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467 [TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo. Jia X; Cheng J; Shen Z; Shao Z; Liu G Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454 [TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma. Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919 [TBL] [Abstract][Full Text] [Related]
16. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction. Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948 [TBL] [Abstract][Full Text] [Related]
17. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891 [TBL] [Abstract][Full Text] [Related]
18. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma. Chen D; Zhu M; Su H; Chen J; Xu X; Cao C J Cell Physiol; 2019 May; 234(5):7257-7265. PubMed ID: 30367453 [TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Sonnemann J; Bumbul B; Beck JF Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]